Harvard-aligned venture capital firm Xfund has reinvested in ImmuneID, which is developing precision immunology therapies based on Harvard University and Johns Hopkins University research.
ImmuneID, a US-based precision immunology drug developer utilising Harvard University and Johns Hopkins University research, completed a $50m series A round yesterday featuring Harvard-aligned venture capital firm Xfund.
The round was led by Alta Partners and included Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, as well as real estate investment manager Redwood Capital Investments, VC firm Section 32 and asset manager Tekla Capital Management.
The round…
